Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists

• Main Authors: Piotr Pankiewicz (Author), Marcin Szybiński (Author), Katarzyna Kisielewska (Author), Filip Gołębiowski (Author), Patryk Krzemiński (Author), Izabela Rutkowska-Włodarczyk (Author), Rafał Moszczyński-Pętkowski (Author), Lidia Gurba-Bryśkiewicz (Author), Monika Delis (Author), Krzysztof Mulewski (Author), Damian Smuga (Author), Jakub Dominowski (Author), Artur Janusz (Author), Michał Górka (Author), Krzysztof Abramski (Author), Agnieszka Napiórkowska (Author), Marcin Nowotny (Author), Krzysztof Dubiel (Author), Katarzyna Kalita (Author), Maciej Wieczorek (Author), Jerzy Pieczykolan (Author), Mikołaj Matłoka (Author)
• Format: Book
• Published: MDPI AG, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

TrkB is a tyrosine kinase receptor that is activated upon binding to brain-derived neurotrophic factor (BDNF). To date, the search for low-molecular-weight molecules mimicking BDNF's action has been unsuccessful. Several molecules exerting antidepressive effects in vivo, such as 7,8-DHF, have b...